AstraZeneca PLC Stock Forecast for 2022 - 2025 - 2030

Updated on 05/25/2022

Stock Rating
3 / 10
Price Target
£145.87
Consensus
Outperform
Upside
39%
Analysts
13
Stock Rating
3
Upside
39%
Analysts
13
Price Target
£145.87

AstraZeneca PLC has an average price target of £145.87 recently offered by thirteen notable experts for 2022, which would represent a potential upside of approximately 39% from the last closing price in May, 2022 if reached. This potential increase is based on a high estimate of £187.20 and a low estimate of £91.84. If you're looking to buy AstraZeneca PLC stock, you may also want to check out its rivals.

£145.87

39% Upside

Outperform
Outperform

AstraZeneca PLC Fair Value Forecast for 2022 - 2025 - 2030

AstraZeneca PLC's Fair Value has seen major growth over the last three years, jumping from £59.51 to £90.99 – an increase of 52.89%. In the next year, analysts predict that Fair Value will reach a reasonable £102.54 – an increase of 12.7%. For the next nine years, the forecast is for Fair Value to grow by 198.83%

2022 Fair Value Forecast
£102.54
2023 Fair Value Forecast
£119.02
2024 Fair Value Forecast
£138.51
2025 Fair Value Forecast
£156.61
2026 Fair Value Forecast
£177.21
2027 Fair Value Forecast
£199.22
2028 Fair Value Forecast
£221.95
2029 Fair Value Forecast
£246.30
2030 Fair Value Forecast
£271.90
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
JNJ Stock Forecast Johnson & Johnson Outperform 3
$181.40 $187.12 1.98% 16
PFE Stock Forecast Pfizer Outperform 7
$53.41 $58.26 2.98% 16
LLY Stock Forecast Eli Lilly and Outperform 5
$305.96 $281.95 4.92% 12
ABBV Stock Forecast AbbVie Outperform 6
$149.11 $152.52 12.5% 19
NOVO B Stock Forecast Novo Nordisk A/S Hold 5
kr655.00 kr678.96 25.19% 11

AstraZeneca PLC Revenue Forecast for 2022 - 2025 - 2030

AstraZeneca PLC's Revenue has seen major growth over the last three years, jumping from £22.09B to £37.42B – an increase of 69.38%. In the next year, analysts predict that Revenue will reach a reasonable £43.24B – an increase of 15.55%. For the next nine years, the forecast is for Revenue to grow by 235.44%

2022 Rev Forecast
£43.24B
2023 Rev Forecast
£50.55B
2024 Rev Forecast
£60.11B
2025 Rev Forecast
£68.89B
2026 Rev Forecast
£78.80B
2027 Rev Forecast
£89.63B
2028 Rev Forecast
£100.80B
2029 Rev Forecast
£112.80B
2030 Rev Forecast
£125.51B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
MRK Stock Forecast Merck Outperform 6
$94.64 $91.73 0.38% 19
ABT Stock Forecast Abbott Laboratories Outperform 7
$113.77 $141.24 23.06% 19
NOVN Stock Forecast Novartis Outperform 7
CHF77.22 CHF103.75 19.24% 12

AstraZeneca PLC Dividend per Share Forecast for 2022 - 2025 - 2030

Over the last three years, AstraZeneca PLC's DPS has increased by 2.5%, going from £2.80 to £2.87. In the next year, analysts are expecting a small increase in EPS, predicting it will reach £2.89 – an increase of 0.81%. The 2030 forecast is for DPS to reach £3.18 or grow by 10.88%.

2022 DPS Forecast
£2.89
2023 DPS Forecast
£2.92
2024 DPS Forecast
£2.97
2025 DPS Forecast
£3.00
2026 DPS Forecast
£3.04
2027 DPS Forecast
£3.07
2028 DPS Forecast
£3.11
2029 DPS Forecast
£3.15
2030 DPS Forecast
£3.18
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BMY Stock Forecast Bristol-Myers Squibb Outperform 8
$77.13 $76.69 1.13% 16
MDT Stock Forecast Medtronic Outperform 4
$105.59 $123.50 15.54% 5
AMGN Stock Forecast Amgen Hold 6
$251.89 $246.46 -0.75% 13

AstraZeneca PLC Free Cash Flow Forecast for 2022 - 2025 - 2030

AstraZeneca PLC's Free Cash Flow has increased by 209.33% in the last three years, going from £1.58B to £4.87B. In the next year, analysts expect Free Cash Flow to reach a reasonable £6.34B – an increase of 30.07%. For the next nine years, the forecast is for Free Cash Flow to grow by 449.31%.

2022 FCF Forecast
£6.34B
2023 FCF Forecast
£8.29B
2024 FCF Forecast
£10.17B
2025 FCF Forecast
£12.38B
2026 FCF Forecast
£14.84B
2027 FCF Forecast
£17.46B
2028 FCF Forecast
£20.34B
2029 FCF Forecast
£23.45B
2030 FCF Forecast
£26.76B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
GSK Stock Forecast GlaxoSmithKline Outperform 1
£17.64 £16.08 2.04% 11
CSL Stock Forecast CSL Outperform 4
$266.28 $228.01 -14.01% 10
GILD Stock Forecast Gilead Sciences Outperform 5
$64.35 $75.96 6.45% 19

AstraZeneca PLC Net Income Forecast for 2022 - 2025 - 2030

In the past three years, AstraZeneca PLC's Net Income has gone down from £2.16B to £112.00M – a 94.8% drop. For next year, the 0 analysts predict earnings per share of £1.18B, which would mean an increase of 957.74%. Over the next nine years, the pros' prediction is Net Income of £1.89T, which would mean a 9-year growth forecast of 1690723.96%.

2022 NI Forecast
£1.18B
2023 NI Forecast
£12.65B
2024 NI Forecast
£136.35B
2025 NI Forecast
£259.94B
2026 NI Forecast
£458.27B
2027 NI Forecast
£735.60B
2028 NI Forecast
£1050.73B
2029 NI Forecast
£1439.40B
2030 NI Forecast
£1893.72B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
MRK Stock Forecast MERCK Kommanditgesellschaft au... Outperform 2
172.40€ 147.51€ 21.81% 15
BDX Stock Forecast Becton, Dickinson and Outperform 5
$257.45 $270.20 10.7% 3
BAYN Stock Forecast Bayer Outperform 5
63.29€ 67.79€ 20.08% 14

AstraZeneca PLC EBITDA Forecast for 2022 - 2025 - 2030

In the past three years, AstraZeneca PLC's EBITDA has significantly grown, increasing from £4.49B to £8.37B – a growth of 86.32%. The next year looks very promising for AstraZeneca PLC, with analysts predicting EBITDA of £9.94B – an increase of 18.72%. Over the next nine years, experts anticipate that AZN's EBITDA will grow at a rate of 233.63%.

2022 EBITDA Forecast
£9.94B
2023 EBITDA Forecast
£11.65B
2024 EBITDA Forecast
£13.57B
2025 EBITDA Forecast
£15.59B
2026 EBITDA Forecast
£17.77B
2027 EBITDA Forecast
£20.10B
2028 EBITDA Forecast
£22.56B
2029 EBITDA Forecast
£25.17B
2030 EBITDA Forecast
£27.93B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
MRNA Stock Forecast Moderna Hold 0
$152.54 $0.00 26.85% 8
4519 Stock Forecast Chugai Pharmaceutical Hold 3
¥3.79k ¥0.00 18.73% 0
LONN Stock Forecast Lonza Group Ltd Outperform 3
CHF607.00 CHF756.46 29.74% 5

AstraZeneca PLC EBIT Forecast for 2022 - 2025 - 2030

In the last three years, AstraZeneca PLC's EBIT has grown by 159.16%, from £1.76B to £4.57B. For the next year, analysts are expecting EBIT to reach a reasonable £5.75B – an increase of 25.82%. Over the next nine years, experts predict that EBIT will grow by 259.37%.

2022 EBIT Forecast
£5.75B
2023 EBIT Forecast
£6.79B
2024 EBIT Forecast
£7.81B
2025 EBIT Forecast
£9.08B
2026 EBIT Forecast
£10.37B
2027 EBIT Forecast
£11.73B
2028 EBIT Forecast
£13.22B
2029 EBIT Forecast
£14.77B
2030 EBIT Forecast
£16.42B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BAS Stock Forecast BASF Outperform 5
48.76€ 78.27€ 31.26% 16
BNTX Stock Forecast BioNTech Hold 0
$284.21 $0.00 -11.75% 3
4568 Stock Forecast Daiichi Sankyo Company Outperform 2
¥2.83k ¥0.00 36.07% 0

AstraZeneca PLC EPS Price Prediction Forecast for 2022 - 2025 - 2030

AstraZeneca PLC's EPS has seen major growth over the last three years, jumping from £3.46 to £5.29 – an increase of 52.89%. In the next year, analysts predict that EPS will reach a reasonable £5.96 – an increase of 12.7%. For the next nine years, the forecast is for EPS to grow by 198.83%

2022 EPS Forecast
£5.96
2023 EPS Forecast
£6.92
2024 EPS Forecast
£8.05
2025 EPS Forecast
£9.11
2026 EPS Forecast
£10.30
2027 EPS Forecast
£11.58
2028 EPS Forecast
£12.90
2029 EPS Forecast
£14.32
2030 EPS Forecast
£15.81
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
ILMN Stock Forecast Illumina Outperform 3
$240.26 $376.81 45.68% 0
BAX Stock Forecast Baxter International Outperform 5
$73.90 $92.47 21.79% 3
BIIB Stock Forecast Biogen Outperform 4
$202.54 $287.21 12.32% 24

© Copyright 2022 | Stock Forecast | All Rights Reserved